Martin Delaney Collaboratories for HIV Cure Research
National Institutes of Health
Classification and identifiers
- Solicitation number
- FOR-AI-27-001
- Assistance listing (CFDA)
- 93.855
Amount
Amount not published by the funder
Who can apply
About this opportunity
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by continuing support for the Martin Delaney Collaboratories (MDCs) for HIV Cure Research. The goal of the MDC program is to develop strategies to control viral replication without the need for lifelong antiretroviral therapy, with an ultimate goal of completely eradicating HIV reservoirs from the individual. The program will also address the unique needs of children living with HIV. The MDC program will accelerate HIV cure research by fostering strategic collaborations among academic institutions, scientists in government, the private sector, and community stakeholders. The program provides economies of scale by leveraging shared reagents, research resources, and specialized technologies in supp...
Related opportunities
- Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV)National Institutes of Health
- Centers for AIDS Research (CFAR)National Institutes of Health
- HIV/AIDS Clinical Trials Network Laboratory CentersNational Institutes of Health
- Integrated Specific Pathogen Free Research Models and Human New Approach Methodologies to Advance HIV/AIDS Research (U42 Clinical Trial Not Allowed)National Institutes of HealthUp to $2.7M
- Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)National Institutes of HealthCloses Sep 2028
- Centers for Structural Biology of HIV and other Infectious DiseasesNational Institutes of Health